This study will be the first to establish pharmacokinetic curves for the etonogestrel
contraceptive implant with scapular subdermal insertion. By obtaining this pharmacokinetic
data, the investigators can compare this data to already published pharmacokinetic data with
conventional implant insertion. This comparison can provide some reassurance that the
absorption and distribution of etonogestrel from the contraceptive implant with scapular
insertion is similar to that found with conventional insertion. With similar pharmacokinetic
properties, the investigators would expect scapular insertion of the implant to maintain
similar contraceptive efficacy for the populations of women that may benefit from this
alternative insertion site. Preliminary safety data will also enrich the understanding of any
potential insertion site side effects with subdermal scapular implant insertion, as the
investigators currently only have a single case report with side effect outcomes. The
investigators can then use this pilot data to support future larger investigations on
subdermal scapular implant insertion given its complete avoidance of the neurovascular
complications associated with arm insertion.